Celator Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CELATOR PHARMS, and when can generic versions of CELATOR PHARMS drugs launch?
CELATOR PHARMS has one approved drug.
There are nine US patents protecting CELATOR PHARMS drugs.
There are one hundred and twenty-nine patent family members on CELATOR PHARMS drugs in twenty-six countries and thirty-six supplementary protection certificates in sixteen countries.
Drugs and US Patents for Celator Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 8,092,828 | ⤷ Sign Up | ⤷ Sign Up | ||||
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 9,271,931 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 10,166,184 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 8,022,279 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 10,835,492 | ⤷ Sign Up | ⤷ Sign Up | ||||
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 8,518,437 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Celator Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2002351626 | ⤷ Sign Up |
Japan | 4972545 | ⤷ Sign Up |
Denmark | 3300601 | ⤷ Sign Up |
Japan | 2017160211 | ⤷ Sign Up |
Japan | 2010519224 | ⤷ Sign Up |
Austria | 475411 | ⤷ Sign Up |
Germany | 60222580 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Celator Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1744764 | C201830057 | Spain | ⤷ Sign Up | PRODUCT NAME: DAUNORUBICINA + CITARABINA; NATIONAL AUTHORISATION NUMBER: EU/1/18/1308; DATE OF AUTHORISATION: 20180823; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1308; DATE OF FIRST AUTHORISATION IN EEA: 20180823 |
3300601 | 301185 | Netherlands | ⤷ Sign Up | PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
2768484 | CR 2019 00051 | Denmark | ⤷ Sign Up | PRODUCT NAME: KOMBINATION AF DAUNORUBICIN OG CYTARABIN; REG. NO/DATE: EU/1/18/1308 20180827 |
2768484 | LUC00135 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827 |
2768484 | 122019000091 | Germany | ⤷ Sign Up | PRODUCT NAME: KOMBINATION VON DAUNORUBICIN UND CYTARABIN; REGISTRATION NO/DATE: EU/1/18/1308 20180823 |
3300601 | 122022000044 | Germany | ⤷ Sign Up | PRODUCT NAME: KOMBINATION VON DAUNORUBICIN UND CYTARABIN; REGISTRATION NO/DATE: EU/1/18/1308 20180823 |
2768484 | 19C1063 | France | ⤷ Sign Up | PRODUCT NAME: COMBINAISON DE DAUNORUBICINE ET CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.